Streetbeat News

Price Targets

OWL

RBC Capital analyst Kenneth Lee has reiterated an Outperform rating on Blue Owl Capital (NYSE: OWL) and maintained a price target of $16.

Portfolio Pulse from Benzinga Newsdesk

November 14, 2023 | 5:02 pm

COP

Over the past 3 months, 9 analysts have provided their ratings on ConocoPhillips (NYSE:COP), with 5 being bullish, 3 somewhat bullish, and 1 indifferent. The average 12-month price target for COP is $143.44, with a high of $160.00 and a low of $125.00. This target has increased by 3.19% over the past month. Analyst ratings are important as they provide investors with insights into stock performance based on financial analysis and industry trends.

Portfolio Pulse from Benzinga Insights

November 14, 2023 | 5:00 pm

HSIC

Within the last quarter, Henry Schein (NASDAQ:HSIC) received mixed analyst ratings, with 1 bullish, 2 somewhat bullish, 1 indifferent, and 1 somewhat bearish rating. The average 12-month price target for HSIC is $74.2, which is a 10.87% decrease from the previous target of $83.25. The high target is $84.00 and the low target is $65.00. Analysts provide these ratings based on research, financial statements, and insider information, although they are subjective and subject to human error.

Portfolio Pulse from Benzinga Insights

November 14, 2023 | 5:00 pm

CMG

Analysts have recently provided ratings for Chipotle Mexican Grill (NYSE:CMG), with 5 bullish, 9 somewhat bullish, and 2 indifferent ratings in the last quarter. The average 12-month price target among 16 analysts is $2212.19, a slight decrease from the previous target of $2222.62. Analysts base their ratings on financial predictions, company performance, and industry research.

Portfolio Pulse from Benzinga Insights

November 14, 2023 | 5:00 pm

LPTX

Raymond James has maintained its Outperform rating for Leap Therapeutics (NASDAQ:LPTX) but reduced its price target from $18.50 to $17.50. Despite the lower target, the new price still implies a significant upside of 1066.67% from the current trading price of $1.50. Leap Therapeutics is a biopharmaceutical company focused on developing cancer treatments, with its main clinical program being DKN-01, targeting tumor-promoting pathways and the immune system.

Portfolio Pulse from Benzinga Insights

November 14, 2023 | 5:00 pm

NYCB

Wedbush has downgraded New York Community Bancorp Inc (NYSE:NYCB) from a previous rating to Underperform, with a new price target set at $8.00, down from $12.00. The current trading price of NYCB shares is $9.01, and the new price target suggests a potential decrease of 11.21%. New York Community Bancorp operates as a bank holding company with multiple divisions across various states.

Portfolio Pulse from Benzinga Insights

November 14, 2023 | 5:00 pm

IART

Integra Lifesciences (NASDAQ:IART) has been rated by 4 analysts in the last quarter, with 1 bullish, 1 indifferent, and 2 somewhat bearish ratings. The average 12-month price target among these analysts is $42.5, with a high of $50.00 and a low of $37.00. This target remains unchanged from the previous average. Analyst ratings are based on predictions of a company's future earnings and revenue, and are updated quarterly or after major company events.

Portfolio Pulse from Benzinga Insights

November 14, 2023 | 5:00 pm

ANF

Telsey Advisory Group has reaffirmed its Outperform rating on Abercrombie & Fitch (NYSE:ANF) and increased its price target from $62.00 to $74.00. Following this news, ANF shares have risen 3.1% to $68.45. The new price target suggests a potential upside of 8.11% from the current price. Abercrombie & Fitch is a specialty retailer with a significant presence in the United States and international markets, operating under various brand names.

Portfolio Pulse from Benzinga Insights

November 14, 2023 | 5:00 pm

AEO

Analysts have provided mixed ratings for American Eagle Outfitters (NYSE:AEO) in the last quarter, with 1 bullish, 1 somewhat bullish, 4 indifferent, and 1 somewhat bearish rating. The average 12-month price target for AEO is $18.0, with a high of $22.00 and a low of $13.00. This target has increased by 12.5% over the past month. Analysts' ratings are based on predictions of a company's future earnings and revenue, and are subject to error.

Portfolio Pulse from Benzinga Insights

November 14, 2023 | 5:00 pm

RC

Keefe, Bruyette & Woods has maintained a Market Perform rating for Ready Capital (NYSE:RC) but lowered its price target from $10.50 to $10.00. Ready Capital's shares are currently trading up 3.0% at $9.95. The new price target suggests a modest 0.5% upside potential. Ready Capital is a real estate finance company involved in small-balance commercial loans and residential mortgage banking.

Portfolio Pulse from Benzinga Insights

November 14, 2023 | 5:00 pm